The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Benefits of rituximab for elderly DLBCL patients
Raul Cordoba, MD, PhD of University Hospital Fundación Jiménez Díaz, Madrid, Spain, outlines the survival benefit of rituximab with or without anthracyclines for the treatment of diffuse large B-cell lymphoma (DLBCL) in patients over the age of 80 years. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
